Bringing Science to Society

Winston J. Churchill


Winston J. Churchill has been a director of the company since 2008. Since 2007, Mr. Churchill has been a director of the corporate general partner of the common general partner of SCP Vitalife, which beneficially owns 33.6% of our outstanding stock as of April 1, 2016. He has also served as a managing member of SCP Vitalife Management Company, LLC, which by contract provides certain management services to the common general partner of SCP Vitalife.

Mr. Churchill has also served since 1993 as the president of CIP Capital Management, Inc., the general partner of CIP Capital, L.P., an SBA-licensed private equity fund. Before that, he was a managing partner of Bradford Associates, which managed private equity funds on behalf of Bessemer Securities Corporation and Bessemer Trust Company.

From 1967 to 1983, Mr. Churchill practiced law at the Philadelphia firm of Saul Ewing, LLP, where he served as chairman of the banking and financial institutions department, chairman of the finance committee, and a member of the executive committee. Mr. Churchill is a director of Griffin Land & Nurseries, Inc., Innovative Solutions and Support, Inc., Amkor Technology, Inc., and various SCP Vitalife portfolio companies. In addition, he serves as a director on the boards of a number of charities and as a trustee of educational institutions, including the Gesu School and Scholar Academies, and is a trustee fellow of Fordham University.

From 1989 to 1993, Mr. Churchill served as chairman of the finance committee of the Pennsylvania Public School Employees’ Retirement System. He was awarded a B.S. in physics, summa cum laude, from Fordham University, followed by an M.A. in economics from Oxford University, where he studied as a Rhodes Scholar and a J.D. from Yale Law School.

As a longtime director of our company, Mr. Churchill’s extensive knowledge of our business and history, experience as a board member of multiple publicly traded and privately held companies, and expertise in developing, financing, and providing strong executive leadership to numerous growing life science companies contributed to our Board’s conclusion that he should serve as a director of our company.